Testing henagliflozin for heart scarring in non-obstructive HCM
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether the drug henagliflozin can reduce scarring in the heart muscle of people with a type of hypertrophic cardiomyopathy that does not block blood flow. It uses special scans to measure scar tissue before and after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a diagnosis of non-obstructive hypertrophic cardiomyopathy (HCM), meaning your heart muscle is thickened but blood flow out of the heart is not blocked.
- You are willing to undergo two special PET and MRI scans using a tracer called FAPI.
- Your initial FAPI PET scan shows increased uptake, indicating active scarring in the heart.
- You have mild to moderate heart failure symptoms (able to do daily activities with some limitation or less).
- You do not have severe heart failure, recent heart surgery, serious liver or kidney problems, or other conditions that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special CT scan to create a 3D model of your heart's blood flow. It aims to see if this model can help doctors better predict how well treatments work for people with a thick heart muscle that blocks blood flow.
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This study tests whether a heart medication (SGLT2 inhibitor) affects fat around the heart's arteries in people who have had a heart attack but do not have diabetes or heart failure. It uses a CT scan to measure changes over time.
This study uses a special PET scan to look for scarring (fibrosis) in the heart muscle of people with heart failure. It may help doctors better understand why some hearts get stiff or weak.
This study uses advanced imaging (PET/MR or PET/CT) to look at scarring (fibrosis) in the heart muscle. It is for people with various heart muscle diseases, including heart failure with preserved pumping, thickened heart muscle, high blood pressure-related heart damage, heart inflammation, and others.
Hear when a new HCM - Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.